2nd Line Relapsed or Metastatic Mucosal HNSCC not NPC

Treatment

No Injectable Lesions

Prior - PD(L)1

Max 2 Prior Therapies

Amenable to Paired Biopsies

ROR2 Positive

Max 4 Prior Therapies in R/M Setting

Injectable Lesions

ECOG-ACRIN-EA3202
Phase III/III Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent / Metastatic Head & Neck Cancers
PI: Khan Sponsor: ECOG-ACRIN

ENT0100
Phase I Multicenter Open Label First-in-Human ABBV-CLS-579 Alone in Combination in Locally Advanced or Metastatic Tumors
PI: Colevas Sponsor: Abbvie Inc.

ENT0088
Phase II Magnolimab Combination Therapy in Head and Neck Squamous Cell Carcinoma
Safety Run-in 2 / Phase 2 Cohort 3
PI: Colevas Sponsor: Gilead Sciences, Inc.

ENT0109
Open-Label Multicenter Dose-escalation Phase I/II Study of INBRX-105 & INBRX-105 in Combo w/ Pembrolizumab in Locally Advanced or Metastatic Solid Tumors
PI: Colevas Sponsor: Inhibrx, Inc.

ENT0108
Phase II Open-Label Study of Ozurutamab Vedotin (BA3021) in PD-1/L1 Failure Patients w/ Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
PI: Colevas Sponsor: BioAtla, Inc.

ENT0105
Phase I/II Study of SRF144 in Patients With Advanced Solid Tumors
PI: Colevas Sponsor: Surface Oncology, Inc.

ENT0064
Phase Ib Ad/PNP-PdaAAM + Co-Admin of Fludarabine Phosphate in Recurrent Local Head and Neck Cancer
PI: Colevas Sponsor: PNP Therapeutics

KEY

Pending
Open for Enrollment
Observational Study
Optional Path
Link
Trial Posting
Extension Study
Enrollment on Hold

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu